INTRODUCTION: Biomarkers for monitoring disease activity and treatment response in peripheral neuropathies remain limited. Big tau, a high-molecular-weight isoform of tau, is predominantly expressed in the peripheral nervous system (PNS). We investigated serum levels of big tau, brain-derived tau (BD-tau), and neurofil...
L. Martín-Aguilar, F. González-Ortiz, H. Zetterberg et al.· medRxiv· 0 citations
Objective: Regression-based normative approaches are widely used in neuropsychology but often rely on score transformations to satisfy model assumptions. We compared previously published linear regression (LR)-based norms with norms derived using Generalized Additive Models for Location, Scale and Shape (GAMLSS) for th...
B. Kirsebom, I. M. Lorentzen, J. Espenes et al.· medRxiv· 0 citations
This study provides Class II evidence that plasma NfL/p-tau217 discriminates patients with CJD from those with AD and Diagnosing AD with a single abnormal p-tau plasma biomarker risks misdiagnosing prion diseases as AD.
Thomas Coysh, Rhiannon Laban, Elena Veleva et al.· Neurology· 0 citations
In vivo evidence is provided for choroid plexus dysfunction in a maternally inherited disorder with convergent evidence supporting a mitochondrial aetiology, associated with reduced CSF production and impaired blood–CSF barrier transport, substantially altering biomarker profiles in the absence of cortical atrophy or b...
P. Selnes, J. Jarholm, Antón Vila-Sanjurjo et al.· Fluids and Barriers of the C...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
